Renaissance Technologies (RenTech)'s VYNE Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 466 shares of VYNE Therapeutics Inc. (VYNE) worth $15,161, representing 0.00% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 20 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in VYNE, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2025, adding 114,644 shares. Largest reduction occurred in Q2 2025, reducing 104,600 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s VYNE Therapeutics (VYNE) Holding Value Over Time
Track share changes against reported price movement
Quarterly VYNE Therapeutics (VYNE) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +120 | Add 34.68% | 466 | $32.53 |
| Q1 2026 | +346 | New Buy | 346 | $29.88 |
| Q3 2025 | -10,543 | Sold Out | 0 | $0.00 |
| Q2 2025 | -104,600 | Reduce 90.84% | 10,543 | $1.65 |
| Q1 2025 | +90,200 | Add 361.62% | 115,143 | $1.58 |
| Q4 2024 | -1,234 | Reduce 71.21% | 499 | $167.45 |
| Q3 2024 | +471 | Add 37.32% | 1,733 | $93.99 |
| Q2 2024 | -350 | Reduce 21.71% | 1,262 | $98.52 |
| Q1 2024 | +684 | Add 73.71% | 1,612 | $153.23 |
| Q4 2023 | +408 | Add 78.46% | 928 | $116.38 |
| Q3 2023 | -202 | Reduce 27.98% | 520 | $201.92 |
| Q2 2023 | +210 | Add 41.02% | 722 | $0.20 |
| Q1 2023 | -451 | Reduce 46.83% | 512 | $0.15 |
| Q4 2022 | -69 | Reduce 6.69% | 963 | $0.13 |
| Q3 2022 | -12 | Reduce 1.12% | 1,032 | $200.58 |
| Q2 2022 | -28 | Reduce 2.65% | 1,044 | $349.62 |
| Q1 2022 | +67 | Add 6.70% | 1,072 | $584.89 |
| Q4 2021 | -378 | Reduce 27.35% | 1,005 | $918.41 |
| Q3 2021 | +1,038 | Add 300.42% | 1,383 | $1251.63 |
| Q2 2021 | +17,274 | New Buy | 345 | $3162.32 |
Renaissance Technologies (RenTech)'s VYNE Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased VYNE Therapeutics Inc. (VYNE) in Q2 2021, acquiring 345 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held VYNE Therapeutics Inc. (VYNE) for 20 quarters since Q2 2021.
Renaissance Technologies (RenTech)'s largest addition to VYNE Therapeutics Inc. (VYNE) was in Q1 2025, adding 115,143 shares worth $181,926.
According to the latest 13F filing for Q2 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 466 shares of VYNE Therapeutics Inc. (VYNE), valued at approximately $15,161.
As of the Q2 2026 filing, VYNE Therapeutics Inc. (VYNE) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in VYNE Therapeutics Inc. (VYNE) was 115,143 shares, as reported at the end of Q1 2025.